CanSino Biologics Inc (CJH) — Cash Flow-to-Debt Ratio
CanSino Biologics Inc (CJH) has a Cash Flow-to-Debt Ratio of -0.10x as of June 2023, meaning its operating cash flow of €-392.00 Million could theoretically repay 0% of its total liabilities (€3.93 Billion) in one year. See CJH cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
CanSino Biologics Inc Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for CanSino Biologics Inc across 10 annual periods. Also explore CJH net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for CanSino Biologics Inc (2016–2025)
Year-by-year debt coverage analysis for CanSino Biologics Inc. For market capitalisation and broader financial context, see CanSino Biologics Inc market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.04x | €77.86 Million | €2.22 Billion | ▲ +163.2% |
| 2024 | -0.06x | €-168.79 Million | €3.05 Billion | ▲ +75.6% |
| 2023 | -0.23x | €-916.25 Million | €4.03 Billion | ▲ +48.2% |
| 2022 | -0.44x | €-1.85 Billion | €4.22 Billion | ▼ -171.1% |
| 2021 | 0.62x | €2.05 Billion | €3.33 Billion | ▲ +219.3% |
| 2020 | -0.52x | €-349.93 Million | €677.22 Million | ▼ -5.2% |
| 2019 | -0.49x | €-154.25 Million | €313.98 Million | ▼ -16.6% |
| 2018 | -0.42x | €-123.64 Million | €293.56 Million | ▼ -93.8% |
| 2017 | -0.22x | €-56.30 Million | €259.03 Million | ▲ +29.4% |
| 2016 | -0.31x | €-34.38 Million | €111.70 Million | — |